This is an updated guideline from Nice on LARC methods. The only real difference is that Implanon is no longer available and that it has been replaced by Nexplanon, hence the guidance had to be updated. There is no other real change to what they are advising.
There is quite a handy appendix, which you can use to give advice regarding side-effects, effectiveness etc.
A useful print-out for patients comes from the FPA.
Latest posts by Louise Hudman (see all)
- Nice | Who should we be testing for cirrhosis? - October 3, 2016
- Nice | Non-alcoholic fatty liver disease NAFLD - August 26, 2016
- Evolocumab and Alirocumab for treating dyslipidaemia - August 25, 2016